Low Allopregnanolone Linked to Depression in Perimenopause
A small observational study presented at The Menopause Society's 2026 meeting links lower levels of a brain-active hormone to more severe depressive symptoms.
Updated on Nov. 3, 2026 in Alzheimer’s
Researchers reported that lower allopregnanolone levels were associated with greater depression symptoms in perimenopausal women. The observational study, shared at The Menopause Society 2026 Annual Meeting in San Diego in October, followed 50 women with untreated mild depression.
Why it matters
Perimenopausal depression is often overlooked, and the findings point to a possible biological link between a neurosteroid and mood during the menopause transition. The researchers suggested further study of allopregnanolone and its synthetic analogues as a potential treatment.
The study measured serum allopregnanolone and weekly MADRS scores in 50 women over 8 weeks, with hormone values available for 40 of them, and found a significant inverse association after adjusting for estradiol, progesterone and vasomotor symptoms (P < .001). Because the study was observational and small, it does not show whether changing allopregnanolone levels would alter depressive symptoms.
The players
The Menopause Society
The Menopause Society is a professional organization of clinicians and researchers focused on menopause care and women's midlife health, and it hosted the 2026 annual meeting where the study was shared.
Mass General Brigham
Mass General Brigham is a major Boston-based academic health system whose researchers led the study.
Weill Cornell Medicine
Weill Cornell Medicine is a medical school and research institution in New York City, where commentator Gaither practices, and Gaither recommended screening for depression during the menopause transition.
The details
Researchers measured serum allopregnanolone at each participant's highest and lowest MADRS depression scores, then calculated associations after adjusting for estradiol, progesterone and how often women had vasomotor symptoms. Participants averaged 48 years of age and a BMI of 28.2.
Timeline
October 2026: Study shared at The Menopause Society 2026 Annual Meeting in San Diego.
Health Landscape
The study extends a line of research presented at The Menopause Society's annual meeting that treats the menopause transition as a period of distinct mood risk rather than a background factor. It positions allopregnanolone as a candidate biological marker in a field where perimenopausal depression has received comparatively little targeted treatment research.
For women in perimenopause who are experiencing low mood, the study underscores that depression during this transition is worth raising with a clinician rather than attributing it solely to life stress. Current findings do not yet change treatment, and any new therapy based on allopregnanolone would require further clinical trials.
The takeaway
Persistent low mood during perimenopause is worth discussing with a healthcare provider, since the study suggests a possible biological contributor that researchers are now exploring for treatment. Track changes in mood alongside other menopause symptoms to help inform that conversation.
Further reading
For broader context on brain health and neurological conditions, explore our Alzheimer's coverage.
Source note: This article includes information reported by Medscape.
